Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis

Devlikamova F.I.; Safina D.R.

doi:https://doi.org/10.17116/jnevro202512502169

Devlikamova F.I.

Kazan State Medical Academy — branch of Russian medical Academy of continuing professional education

ORCID: 0000-0003-4411-7051

Safina D.R.

Kazan Federal University

ORCID: 0000-0002-6466-4979

Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis

Authors:

Devlikamova F.I., Safina D.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2): 69‑79

DOI: 10.17116/jnevro202512502169

Read: 2769 times

Contact the author

Table of contents

To cite this article:

Devlikamova FI, Safina DR. Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):69‑79. (In Russ.)
https://doi.org/10.17116/jnevro202512502169

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

OBJECTIVE

To determine the efficacy and safety of Actitropil (fonturacetam) in asthenia.

MATERIAL AND METHODS

This meta-analysis includes the studies results on fonturacetam efficacy in asthenia. After checking for the risk of bias and the risk of systematic errors, the meta-analysis included 11 articles. The efficacy and safety of fonturacetam at a daily dose of 200 mg was assessed, since patients received this dose in all included studies.

RESULTS

The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1—53.7). In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85—23.85 points) (p<0.0001). Additional effects of fonturacetam: positive effect on emotional background, sleep, cognitive functions, quality of life. High patient satisfaction with treatment was observed. During treatment with fonturacetam, the frequency of side effects averaged 5.5%. Side effects were transient and completely regressed within a week of continued treatment.

CONCLUSION

Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.

Keywords:

fonturacetam

Actitropil

asthenic syndrome

chronic fatigue syndrome

effectiveness

safety

Authors:

Devlikamova F.I.

Kazan State Medical Academy — branch of Russian medical Academy of continuing professional education

ORCID: 0000-0003-4411-7051

Safina D.R.

Kazan Federal University

ORCID: 0000-0002-6466-4979

Received:

20.01.2025

Accepted:

27.01.2025

Close metadata

References:

Akhapkina VI, Fedin AI, Avedisova AS, Akhapkin RV. Effektivnost’ fenotropila pri lechenii astenicheskogo sindroma i sindroma khronicheskoi ustalosti. Atmosphere. Nervnye Bolezni. 2004;3:28-32. (In Russ.).
Vorob’eva OV. Mnogogrannost’ fenomena astenii. Russkii Meditsinskii Zhurnal. 2012;20(5):248. (In Russ.).
Lebedev MA, Palatov SYu, Kovrov GV, et al. Asthenia: symptom, syndrome, disease. Effective pharmacotherapy. Neurology and Psychiatry. 2014;1:30-38. (In Russ.).
The State Reference Register of medicines. Fonturacetam. (In Russ.). Available by reference: https://grls.rosminzdrav.ru/grls.aspx?s=%D1%84%D0%BE%D0%BD%D1%82%D1%83%D1%80%D0%B0%D1%86%D0%B5%D1%82%D0%B0%D0%BC&m=mnn
Bekuzarova MR, Kumakhov AA. Clinical and laboratory evaluation of the effectiveness of the nootropic drug Actitropil (fonturacetam) in the treatment of asthenic syndrome. Consilium Medicum. 2023;25(11):728-735. (In Russ.). https://doi.org/10.26442/20751753.2023.11.202576
Devlikamova FI. Effektivnost’ i bezopasnost’ preparata Aktitropil u patsientov s astenicheskim sindromom: rezul’taty nablyudatel’noi klinicheskoi programmy. Nervnye Bolezni. 2022;4:36-46. (In Russ.). https://doi.org/10.24412/2226-0757-2022-12933
Vizilo TL. Efficacy and safety of the Actitropil in the treatment of reactive asthenia in young patients. Farmateka. 2023;30(9-10):148-155. (In Russ.). https://doi.org/10.18565/pharmateca.2023.9-10.159-166
Andreyev VV. Experience of using Actitropil in chronic cerebral ischemia: clinical follow-up results. RMZh. Medical Inquiry. 2023;7(10):620-624. (In Russ.). https://doi.org/10.32364/2587-6821-2023-7-10-2
Fedin AI, Amcheslavskaya EV, Krasnoperov EN, Belopasova AV. Primenenie Fenotropila u bol’nykh s khronicheskoi ishemiei mozga i umerennymi kognitivnymi narusheniyami. Rezul’taty randomizirovannogo dvoinogo slepogo platsebokontroliruemogo issledovaniya. Nervnye Bolezni. 2010;3:22-30. (In Russ.).
Yur’eva LN, Dukel’skii AA, Shusterman TI, et al. Otsenka effektivnosti deistviya preparata fenilpiratsetam (Entrop) pri lechenii patsientov s asteniei organicheskogo i nevroticheskogo geneza. Psikhiatriya, Psikhoterapiya i Klinicheskaya Psikhologiya. 2019;10(1):135-147. (In Russ.).
Medvedev VE, Frolova VI, Epifanov AV. New possibilities of pharmacotherapy in cardiovascular patients with mental disorders. SS. Korsakov Journal of Neurology and Psychiatry. 2014;114(9):30-37. (In Russ.).
Nazarov VV, Kolchev AI, Kalinskii PP. Klinicheskie osobennosti astenicheskogo sindroma u lits molodogo vozrasta perenesshikh ishemicheskii insul’t. Rossiiskii Biomeditsinskii Zhurnal. 2008;9:323-331. (In Russ.).
Mokina TV, Antipenko EA, Gustov AV. Effektivnost’ Fenotropila pri lechenii astenicheskogo sindroma u bol’nykh distsirkulyatornoi entsefalopatiei. Lechebnoe Delo. 2010;4:68-72. (In Russ.).
Zhukova NG, Masenko AYa, Kuznetsova KS, et al. Neurometabolic Therapy for Parkinson’s Disease. Lechaschi Vrach. 2023;6(26):62-68. (In Russ.). https://doi.org/10.51793/OS.2023.26.6.009
Zvejniece L, Svalbe B, Veinberg G, et al. Investigation into stereoselective pharmacological activity of phenotropil. Basic Clin Pharmacol Toxicol. 2011;109(5):407-412. https://doi.org/10.1111/j.1742-7843.2011.00742.x
Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287-312. https://doi.org/10.2165/11319230-000000000-00000
Zvejniece L, Svalbe B, Vavers E, et al. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Pharmacol Biochem Behav. 2017;160:21-29. https://doi.org/10.1016/j.pbb.2017.07.009
Kovalev GI, Akhapkina VI, Abaimov DA, Firstova YuYu. Fenotropil kak retseptornyi modulyator sinapticheskoi neiroperedachi. Atmosfera. Nervnye Bolezni. 2007;4:22-26. (In Russ.).